Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data

Given the limited real-world data of caplacizumab, our multicenter real-world study was designed to assess the safety and efficacy of caplacizumab in immune thrombotic thrombocytopenic pupura (iTTP), compared to historic controls. We have studied 70 patients: 23 in the caplacizumab and 47 in the his...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavriilaki, Eleni, Nikolousis, Emmanuel, Koravou, Eudoxia-Evaggelia, Dimou-Besikli, Sotiria, Kartsios, Charalampos, Papakonstantinou, Anna, Mpanti, Anastasia, Pontikoglou, Charalampos, Kalpadaki, Christina, Bitsani, Aikaterini, Tassi, Ilianna, Touloumenidou, Tasoula, Chatziconstantinou, Thomas, Papathanasiou, Maria, Syrigou, Antonia, Ztriva, Eleutheria, Kaiafa, Georgia, Mandala, Evdokia, Mellios, Zois, Karakasis, Dimitrios, Kourakli, Alexandra, Symeonidis, Argiris, Kapsali, Eleni, Papadaki, Helen H., Lalayanni, Chrysavgi, Sakellari, Ioanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600458/
https://www.ncbi.nlm.nih.gov/pubmed/37901415
http://dx.doi.org/10.3389/fmed.2023.1226114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600458/
https://www.ncbi.nlm.nih.gov/pubmed/37901415
http://dx.doi.org/10.3389/fmed.2023.1226114

Ejemplares similares